Assessing Naltrexone Prescribing and Barriers to Initiation for Alcohol Use Disorder: A Multidisciplinary, Multisite Survey
To survey barriers in prescribing naltrexone for alcohol use disorder. A 12-question survey related to naltrexone prescribing patterns, perceptions, and knowledge was sent to 770 prescribers in the departments of internal medicine, family medicine, and psychiatry across a health system with sites in...
Saved in:
Published in | Frontiers in psychiatry Vol. 13; p. 856938 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
10.05.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | To survey barriers in prescribing naltrexone for alcohol use disorder.
A 12-question survey related to naltrexone prescribing patterns, perceptions, and knowledge was sent to 770 prescribers in the departments of internal medicine, family medicine, and psychiatry across a health system with sites in Arizona, Florida, and Minnesota.
Responses were obtained and included for 146/770 prescribers (19.0% response rate). Most respondents were in the department of internal medicine (
= 94, 64.4%), but the departments of psychiatry (
= 22, 15.1%) and family medicine (
= 30, 20.5%) were also represented. Only 34 (23.3%) respondents indicated they had prescribed naltrexone in the previous 3 months. The most common reasons for not prescribing naltrexone were "unfamiliarity with naltrexone for treatment of alcohol use disorder" and "patients do not have appropriate follow-up or are not in a formal treatment program." Compared with those representing internal/family medicine, psychiatry respondents were more likely to prescribe naltrexone and answer knowledge questions correctly.
In this survey among primarily non-addiction-trained prescribers, a disparity was shown for prescribing naltrexone and in knowledge barriers between staff in internal/family medicine and psychiatry. There exist opportunities for education and quality improvement that promote the prescribing of naltrexone for alcohol use disorder by non-addiction specialists. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Nazzareno Cannella, University of Camerino, Italy Reviewed by: Daniel Roche, University of Maryland School of Medicine, United States; Jennifer Ellis, Johns Hopkins Medicine, United States This article was submitted to Psychopharmacology, a section of the journal Frontiers in Psychiatry |
ISSN: | 1664-0640 1664-0640 |
DOI: | 10.3389/fpsyt.2022.856938 |